Highlights
- Imugene’s new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona.
- The abstract presented was about ‘HERIZON: A Phase 2 study of HER-Vaxx (IMU-131)’.
- The World Congress on Gastrointestinal Cancer has been the foundation for bringing forth progressive and innovative research work relating gastrointestinal cancer.
In the latest announcement, clinical-stage immuno-oncology company Imugene Limited (ASX: IMU) revealed that its latest HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona.
Triggered by the ASX announcement, IMU shares jumped by over 7.8% and were trading at AU$0.096 at the time of writing on 30 June 2023, with a market capitalisation of AU$571.65 million.
Key details of the presentation
The abstract is titled, “HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER-2-targeting peptide vaccine plus SOC chemotherapy in patients with HER-2+ advanced stomach Cancer — Correlation of the antibody responses and clinical outcome.”
The presentation was delivered at the event by Dr Joshua Tobias, Medical University of Vienna, Austria on 29 June 2023 during a session titled ‘Basic Gastric Cancer – Biomarkers and Translational Research.’
Data source: IMU update